Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 2/20 | 0.36 |
| ▸ | ARG2 | P78540 | 2/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953203 | 0.76 | HRH4 (0.44) | HRH4HRH1FDPSBRS3BAZ2B | |
| SCHEMBL13953202 | 0.76 | ARG1 (0.38) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL16705065 | 0.75 | HRH4 (0.54) | HRH4HRH1FDPSARG1ARG2 | |
| SCHEMBL14499112 | 0.74 | HRH4 (0.42) | HRH4HRH1FDPSBRS3DGAT1 | |
| SCHEMBL13953003 | 0.73 | GPR84 (0.45) | BRS3 | |
| SCHEMBL14499113 | 0.73 | HRH4 (0.41) | HRH4HRH1FDPSBRS3DGAT1 | |
| SCHEMBL13953244 | 0.72 | ARG1 (0.36) | ARG1ARG2MEN1KMT2A | |
| SCHEMBL889024 | 0.71 | HRH4 (0.55) | HRH4HRH1FDPSCYP1A2 | |
| SCHEMBL889061 | 0.69 | — | — | |
| SCHEMBL2622475 | 0.69 | S1PR1 (0.42) | ARG1ARG2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | HRH4 1490/4885HRH1 1412/4885FDPS 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.